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Background
Soluble guanylyl cyclase (sGC) plays an important role in
cardiovascular homeostasis and its activity is crucial for
maintaining vascular plasticity. Diminished sGC expres-
sion and activity is associated with the development of
endothelial dysfunction and increase in vascular stiffness.
We have previously demonstrated that alternative splicing
of sGC transcripts produces sGC splice forms with altered
enzymatic and regulatory properties. However, splicing of
sGC genes in human aortic tissue was never investigated.
Results
We demonstrate that a1 and b1 sGC genes undergo alter-
native splicing in human aorta. In normal aortas we
detected expression of four different transcripts for a1 and
b1 sGC genes, each encoding an alternative protein iso-
form. Next, we investigated if sGC splicing is altered in
vascular disease. Total RNA was isolated from samples
collected from patients who underwent aortic repair sur-
gery due to damages associated with aortic diseases (aortic
dissection, aortic aneurism or advanced atherosclerosis).
Age and gender-matched aortic controls from cardiovas-
cular (CV) healthy donors obtained from commercial
sources (Capital Biosciences, MD) were used for compari-
son. Semi-quantitative RT-PCR analysis with primers spe-
cific to individual sGC transcripts demonstrated increased
expression of inhibitory a1 sGC splice variants (a1-Tran-
script 6 and a1-Transcript 7, NCBI) in samples obtained
from aortas of patients with descending and ascending
aortic aneurisms. N1-a1 splice isoform, encoded by
a1-Tr6, was previously demonstrated to have a dominant-
negative phenotype, when co-expressed with canonical a1
and b1 subunits. In presented study, we characterized
the activity of sGC heterodimer containing a1-isoform
D (a1-Tr7) in Cos-7 cells. Although a1-isoform D formed
a heterodimer with b1 sGC, the resulting enzyme had very
low activity and significantly reduced response to major
sGC modulators, including NO-donors, BAY41-2272,
HMR1766 and cobinamide. Thus, increased expression of
a1-Tr7 D should decrease sGC function in human aorta.
On the another hand, expression of oxidation resistant
isoform C-a1 sGC, encoded by a1-Tr5, was reduced in
diseased samples as compared with healthy ones. The dif-
ference was most pronounced between descending aortic
aneurism samples and normal controls. Western blot ana-
lysis of aortic lysates showed decreased level of 50 kDa
C-a1 protein, confirming that C-a1 expression is impaired
in diseased samples. We previously demonstrated that oxi-
dative stress induces the expression of C-a1 sGC in
human cancer cells through modulation of splicing. Here,
we investigated if similar process occurs in vascular
smooth muscle cells (VSMC) treated with hydrogen per-
oxide. Indeed, human aortic VSMC from cardiovascular
healthy donor showed induction of C-a1 transcript in
response to the treatment. This result allows us to suggest
that preferential splicing of C-a1 supports sGC activity in
oxidative environment and its deregulation contributes to
vascular disease. In addition, q-PCR analysis with com-
mercial assays targeted to the conserved transcripts
sequences demonstrated increase in total a1 and b1 sGC
mRNA. Thus, our data indicate that not changes in tran-
scription, but rather deregulation of splicing of sGC genes,
might be a contributing factor to diminished sGC function
in diseased aortas.
Conclusion
Our data indicate that alternative splicing is one of the
mechanisms regulating sGC function in human aorta and
could serve as potential target for new therapeutics.
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